In short
Gedatolisib is an investigational drug being studied in clinical trials for the treatment of various types of cancer, particularly breast cancer. This article explores the ongoing research on gedatolisib, its potential benefits, and its use in combination with other cancer therapies. Clinical trials are evaluating gedatolisib's effectiveness in different cancer types and stages, as well as its safety profile and optimal dosing regimens.
At a glance
- Drug Name
- Gedatolisib (also known as PF-05212384 or PKI-587)
- Mechanism of Action
- Potent, reversible dual inhibitor targeting PI3K and mTOR
- Administration
- Intravenous (IV), typically weekly
- Cancer Types Studied
- Breast cancer (HER2+, triple-negative, HR+/HER2-), lung cancer, pancreatic cancer, head and neck cancer
- Combination Therapies
- Fulvestrant, palbociclib, talazoparib, trastuzumab, paclitaxel, carboplatin
- Key Clinical Trials
- VIKTORIA-1, GLACIER, various Phase 1/2 studies
- Primary Outcomes
- Safety, tolerability, maximum tolerated dose, progression-free survival, objective response rate
- Secondary Outcomes
- Overall survival, duration of response, clinical benefit rate, quality of life measures
- Current Status
- Investigational drug in various phases of clinical trials
What is Gedatolisib?
Gedatolisib is an investigational drug being studied for its potential in treating various types of cancer. It is also known by other names such as PF-05212384 and PKI-587. This medication is part of a class of drugs called PI3K/mTOR inhibitors, which means it works by blocking specific proteins that are involved in cancer cell growth and survival.
How Does Gedatolisib Work?
Gedatolisib is a potent, reversible dual inhibitor that targets two important proteins in cancer cells:
- PI3K (phosphoinositide 3-kinase): This protein is involved in cell growth and survival.
- mTOR (mammalian target of rapamycin): This protein also plays a role in cell growth and metabolism.
By blocking these proteins, gedatolisib may help slow down or stop the growth of cancer cells. This dual action makes gedatolisib a promising candidate for cancer treatment, as it targets multiple pathways that cancer cells use to grow and spread.
What Types of Cancer Does Gedatolisib Treat?
Gedatolisib is being studied for its potential in treating several types of cancer, including:
- Breast cancer: Particularly in patients with HR-positive (hormone receptor-positive), HER2-negative advanced or metastatic breast cancer.
- Triple-negative breast cancer (TNBC): This is a type of breast cancer that lacks estrogen receptors, progesterone receptors, and HER2 protein.
- Non-small cell lung cancer (NSCLC): Specifically, advanced squamous cell lung cancer.
- Pancreatic cancer.
- Head and neck cancer.
It's important to note that gedatolisib is still in the research phase, and its effectiveness for these cancers is being evaluated through clinical trials.
Clinical Trials and Research
Gedatolisib is currently being studied in various clinical trials to assess its safety and effectiveness. Some key studies include:
- VIKTORIA-1 trial: This is a Phase 3 study comparing gedatolisib combined with fulvestrant (a hormone therapy) and with or without palbociclib (another targeted therapy) to standard-of-care therapies in patients with HR-positive, HER2-negative advanced breast cancer.
- Combination therapy studies: Researchers are investigating gedatolisib in combination with other drugs such as palbociclib, talazoparib, and darolutamide for various types of cancer.
- Early-stage breast cancer study: A trial called "GLACIER" is looking at gedatolisib and hydroxychloroquine for preventing breast cancer recurrence in patients with early-stage disease.
These trials aim to determine the best ways to use gedatolisib, its optimal dosage, and which patients might benefit most from this treatment.
Administration and Dosage
Gedatolisib is typically administered intravenously (through a vein). The dosage and schedule can vary depending on the specific clinical trial and the type of cancer being treated. Some common dosing regimens include:
- 180 mg given weekly for 3 weeks, followed by 1 week off.
- 150 mg to 180 mg given weekly.
The exact dosage and schedule will be determined by your healthcare team based on your individual case and the specific treatment protocol.
Potential Side Effects
As gedatolisib is still in clinical trials, the full range of potential side effects is not yet known. However, common side effects observed in cancer treatments targeting similar pathways may include:
- Fatigue
- Nausea
- Diarrhea
- Decreased appetite
- Changes in blood cell counts
Your healthcare team will monitor you closely for any side effects during treatment and adjust the dosage if necessary.
Combination Therapies
Gedatolisib is often studied in combination with other cancer treatments to potentially enhance its effectiveness. Some common combination therapies include:
- Gedatolisib + Fulvestrant: Fulvestrant is a hormone therapy used in breast cancer treatment.
- Gedatolisib + Palbociclib: Palbociclib is a CDK4/6 inhibitor also used in breast cancer treatment.
- Gedatolisib + Talazoparib: Talazoparib is a PARP inhibitor being studied in combination with gedatolisib for breast cancer.
- Gedatolisib + Darolutamide: This combination is being studied for prostate cancer treatment.
These combination therapies aim to target cancer cells through multiple pathways, potentially increasing the effectiveness of treatment.